JP2018515474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515474A5 JP2018515474A5 JP2017556652A JP2017556652A JP2018515474A5 JP 2018515474 A5 JP2018515474 A5 JP 2018515474A5 JP 2017556652 A JP2017556652 A JP 2017556652A JP 2017556652 A JP2017556652 A JP 2017556652A JP 2018515474 A5 JP2018515474 A5 JP 2018515474A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- weeks
- administered
- tissue sample
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 7
- 201000001441 melanoma Diseases 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 238000005259 measurement Methods 0.000 claims 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 238000009097 single-agent therapy Methods 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021037372A JP2021105001A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| JP2024018859A JP2024063028A (ja) | 2015-04-28 | 2024-02-09 | 抗ｐｄ－１抗体を使用するｐｄ－ｌ１陽性黒色腫の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153954P | 2015-04-28 | 2015-04-28 | |
| US62/153,954 | 2015-04-28 | ||
| PCT/US2016/029878 WO2016176504A1 (en) | 2015-04-28 | 2016-04-28 | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037372A Division JP2021105001A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018515474A JP2018515474A (ja) | 2018-06-14 |
| JP2018515474A5 true JP2018515474A5 (enExample) | 2019-06-13 |
Family
ID=56069213
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556652A Pending JP2018515474A (ja) | 2015-04-28 | 2016-04-28 | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| JP2021037372A Pending JP2021105001A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| JP2024018859A Pending JP2024063028A (ja) | 2015-04-28 | 2024-02-09 | 抗ｐｄ－１抗体を使用するｐｄ－ｌ１陽性黒色腫の処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037372A Pending JP2021105001A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| JP2024018859A Pending JP2024063028A (ja) | 2015-04-28 | 2024-02-09 | 抗ｐｄ－１抗体を使用するｐｄ－ｌ１陽性黒色腫の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20160362489A1 (enExample) |
| EP (1) | EP3288980B1 (enExample) |
| JP (3) | JP2018515474A (enExample) |
| KR (2) | KR20250107941A (enExample) |
| ES (1) | ES2861352T3 (enExample) |
| WO (1) | WO2016176504A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| IL318221A (en) | 2012-05-15 | 2025-03-01 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting PD–1/PD–L1 signaling |
| US10174113B2 (en) | 2015-04-28 | 2019-01-08 | Bristol-Myers Squibb Company | Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody |
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| AU2016305697B2 (en) | 2015-08-11 | 2023-02-02 | WuXi Biologics Ireland Limited | Novel anti-PD-1 antibodies |
| CA2993432A1 (en) | 2015-09-01 | 2017-03-09 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| RS67037B1 (sr) * | 2015-11-18 | 2025-08-29 | Bristol Myers Squibb Co | Lečenje kancera pluća korišćenjem kombinacije anti‑pd‑1 antitela i anti‑ctla‑4 antitela |
| WO2018049417A1 (en) | 2016-09-12 | 2018-03-15 | Intra-Cellular Therapies, Inc. | Novel uses |
| BR112019011582A2 (pt) | 2016-12-07 | 2019-10-22 | Agenus Inc. | anticorpos e métodos de utilização dos mesmos |
| PT3565844T (pt) * | 2017-01-09 | 2023-05-02 | Tesaro Inc | Métodos de tratamento de cancro com anticorpos anti-pd-1 |
| CN110637031B (zh) * | 2017-03-04 | 2024-04-16 | 湘潭腾华生物科技有限公司 | 程序性死亡蛋白1(pd-1)的重组抗体及其用途 |
| WO2018183408A1 (en) * | 2017-03-31 | 2018-10-04 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody |
| SG11201908396PA (en) | 2017-03-31 | 2019-10-30 | Bristol Myers Squibb Co | Methods of treating tumor |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| SG11201909955XA (en) | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| CN110720039A (zh) | 2017-05-30 | 2020-01-21 | 百时美施贵宝公司 | Lag-3阳性肿瘤的治疗 |
| CN118356488A (zh) | 2017-05-30 | 2024-07-19 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
| EP3421607A1 (en) * | 2017-06-29 | 2019-01-02 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Identification and elimination of damaged and/or senescent cells |
| US20200239577A1 (en) | 2017-10-15 | 2020-07-30 | Bristol-Myers Squibb Company | Methods of treating tumor |
| WO2019083971A1 (en) | 2017-10-23 | 2019-05-02 | Children's Medical Center Corporation | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY |
| WO2019084313A1 (en) * | 2017-10-27 | 2019-05-02 | Board Of Regents, The University Of Texas System | USE OF SDHA AS PROGNOSTIC MARKER AND THERAPEUTIC TARGET FOR UREAL MELANOMA |
| JP2021506968A (ja) * | 2017-12-18 | 2021-02-22 | デビオファーム・インターナショナル・エス・アーＤｅｂｉｏｐｈａｒｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓ．Ａ． | 癌を治療するためのアゴニスト抗ＰＤ−１抗体とＧｎＲＨアゴニスト又はアンタゴニストとの併用 |
| BR112020015915A8 (pt) * | 2018-02-13 | 2023-01-31 | Merck Sharp & Dohme | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer |
| CN120919306A (zh) | 2018-02-13 | 2025-11-11 | 默沙东有限责任公司 | 用抗pd-1抗体治疗癌症的方法 |
| EP3768384B1 (en) | 2018-03-21 | 2025-06-25 | Olatec Therapeutics, Inc. | Methods for treating melanoma |
| AU2019374748A1 (en) * | 2018-11-05 | 2021-05-27 | Merck Sharp & Dohme Llc | Dosing regimen of anti-LAG3 antibody and combination therapy with anti-PD-1 antibody for treating cancer |
| WO2020097139A1 (en) | 2018-11-07 | 2020-05-14 | Merck Sharp & Dohme Corp. | Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| WO2020118208A1 (en) * | 2018-12-07 | 2020-06-11 | Arizona Board Of Regents On Behalf Of The University Of Arizona | A method of determining risk for skin cancer development and skin cancer therapeutic prevention by measuring pd-1/pd-l1 signaling pathway members |
| WO2020146384A1 (en) * | 2019-01-07 | 2020-07-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN113244386A (zh) * | 2020-02-13 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗肿瘤中的用途 |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| HU228477B1 (en) | 1999-08-23 | 2013-03-28 | Dana Farber Cancer Inst Inc | Pd-1, a receptor for b7-4, and uses therefor |
| CA2589418A1 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| WO2001054732A1 (en) | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| PL1907424T3 (pl) | 2005-07-01 | 2015-12-31 | Squibb & Sons Llc | Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1) |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| US8354509B2 (en) | 2007-06-18 | 2013-01-15 | Msd Oss B.V. | Antibodies to human programmed death receptor PD-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| RU2017132160A (ru) | 2008-12-09 | 2019-02-08 | Дженентек, Инк. | Антитела к pd-l1 и их применение для усиления функции t-клеток |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| EP2699264B1 (en) | 2011-04-20 | 2018-03-14 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112013032552A2 (pt) | 2011-07-24 | 2017-12-12 | Curetech Ltd | variantes de anticorpos monoclonais humanizados imunomoduladores |
| IL318221A (en) * | 2012-05-15 | 2025-03-01 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting PD–1/PD–L1 signaling |
| EP3044234B9 (en) | 2013-09-13 | 2020-08-26 | BeiGene Switzerland GmbH | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| ES2728578T3 (es) * | 2013-09-20 | 2019-10-25 | Bristol Myers Squibb Co | Combinación de anticuerpos anti-LAG-3 y anticuerpos anti-PD-1 para tratar tumores |
| MX2016014753A (es) | 2014-05-15 | 2017-03-06 | Bristol Myers Squibb Co | Tratamiento de cancer de pulmon con el uso de una combinacion de un anticuerpo de muerte anti-programada 1 (anti-pd-1) y otro agente anti-cancerigeno. |
| MA40344A (fr) * | 2014-07-18 | 2016-01-21 | Advaxis Inc | Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer |
| AU2015339306B2 (en) * | 2014-10-29 | 2021-07-22 | Bristol-Myers Squibb Company | Combination therapy for cancer |
| MX2017007390A (es) * | 2014-12-16 | 2017-11-06 | Bristol Myers Squibb Co | Uso de inhibidores de punto de control inmunitario en neoplasmas de sistemas nerviosos centrales. |
| RS60753B1 (sr) | 2015-04-17 | 2020-10-30 | Bristol Myers Squibb Co | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| WO2016196228A1 (en) * | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
| US10392442B2 (en) * | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
| JP2019503387A (ja) * | 2016-01-27 | 2019-02-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および別の抗癌剤の組合せを用いる肺癌の処置法 |
| KR102760684B1 (ko) * | 2017-09-29 | 2025-01-24 | 브리스톨-마이어스 스큅 컴퍼니 | 암을 치료하기 위한 조성물 및 방법 |
-
2016
- 2016-04-28 KR KR1020257021485A patent/KR20250107941A/ko active Pending
- 2016-04-28 WO PCT/US2016/029878 patent/WO2016176504A1/en not_active Ceased
- 2016-04-28 ES ES16724512T patent/ES2861352T3/es active Active
- 2016-04-28 JP JP2017556652A patent/JP2018515474A/ja active Pending
- 2016-04-28 KR KR1020177033883A patent/KR20170140316A/ko not_active Ceased
- 2016-04-28 US US15/141,772 patent/US20160362489A1/en not_active Abandoned
- 2016-04-28 EP EP16724512.5A patent/EP3288980B1/en active Active
-
2019
- 2019-06-03 US US16/430,106 patent/US20200010549A1/en not_active Abandoned
-
2021
- 2021-03-09 JP JP2021037372A patent/JP2021105001A/ja active Pending
-
2022
- 2022-03-22 US US17/701,436 patent/US20220281974A1/en active Pending
-
2024
- 2024-02-09 JP JP2024018859A patent/JP2024063028A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515474A5 (enExample) | ||
| JP2018514550A5 (enExample) | ||
| JP2018522887A5 (enExample) | ||
| JP2019510733A5 (enExample) | ||
| JP2018520657A5 (enExample) | ||
| JP2023159353A (ja) | Ｔ細胞疲弊を予防および逆転するためのエピジェネティック標的および転写標的の同定 | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| HRP20230237T1 (hr) | Anti-psma antitijela, bispecifične molekule za vezanje antigena koje vežu psma i cd3, i njihova uporaba | |
| RU2017116847A (ru) | Антитела к pd-1 | |
| EP4464333A3 (en) | Anti-death receptor antibodies and methods of use thereof | |
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| MY204740A (en) | Antagonistic cd40 monoclonal antibodies and uses thereof | |
| RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
| EA201590208A1 (ru) | Усиление активности т-клеток car путем совместного введения биспецифического антитела | |
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| BR112016013338A2 (pt) | anticorpo pd-1, fragmento de ligação do antígeno do mesmo e uso médico do mesmo | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2018501197A5 (enExample) | ||
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| JP2016509009A5 (enExample) | ||
| JP2020500542A5 (enExample) | ||
| HRP20210399T1 (hr) | Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) | |
| JP2018508483A5 (enExample) | ||
| JP2017518366A5 (enExample) |